The Structure and Function of Francisella Lipopolysaccharide

Overview

Journal Ann N Y Acad Sci

Specialty Science

Date 2007 Mar 31

PMID 17395723

Citations 90

Authors

John S Gunn

Robert K Ernst

Affiliations

Soon will be listed here.

Abstract

A key factor in the biology of Francisella spp. is lipopolysaccharide (LPS). Francisella LPS has many unique structural properties and poorly activates proinflammatory responses due to its lack of interaction with toll-like receptor 4 (TLR4). The LPS of this organism can be modified by various carbohydrates including glucose, mannose and galactosamine, which affect various aspects of virulence. Spontaneously occurring colony variants of F. tularensis have altered LPS. This altered LPS may account for the novel phenotypes of these variants that include effects on susceptibility to killing by normal human serum, intracellular survival and animal virulence. Mutants devoid of O-antigen (directed mutants in O-antigen biosynthetic genes) show reduced intracellular survival and mouse virulence. Thus, this surface component is important in F. tularensis pathogenesis, and the inability of the LPS to alarm the immune system coupled with its frequent modification/alteration likely aid the success of this pathogen during human infection.

Citing Articles

DMEM and EMEM are suitable surrogate media to mimic host environment and expand leptospiral pathogenesis studies using tools.

Garcia L, Lin Z, Culos S, Muenker M, Johnson E, Wang Z bioRxiv. 2025; .

PMID: 39896660 PMC: 11785191. DOI: 10.1101/2025.01.22.634353.

Insights into ubiquitinome dynamics in the host‒pathogen interplay during Francisella novicida infection.

Yang L, Li Y, Xie Q, Xu T, Qi X Cell Commun Signal. 2024; 22(1):508.

PMID: 39425216 PMC: 11487746. DOI: 10.1186/s12964-024-01887-1.

Development, Strategies, and Challenges for Tularemia Vaccine.

Moradkasani S, Maurin M, Salek Farrokhi A, Esmaeili S Curr Microbiol. 2024; 81(5):126.

PMID: 38564047 DOI: 10.1007/s00284-024-03658-0.

Current vaccine strategies and novel approaches to combatting Francisella infection.

Harrell J, Roy C, Gunn J, McLachlan J Vaccine. 2024; 42(9):2171-2180.

PMID: 38461051 PMC: 11095077. DOI: 10.1016/j.vaccine.2024.02.086.

Genetically divergent associated with septic arthritis, Montevideo, Uruguay.

Riera N, Salazar C, Rivera B, Galiana A, Duran R, Portela M New Microbes New Infect. 2024; 57:101210.

PMID: 38261949 PMC: 10797181. DOI: 10.1016/j.nmni.2023.101210.

References

Gunn J, Ryan S, van Velkinburgh J, Ernst R, MILLER S . Genetic and functional analysis of a PmrA-PmrB-regulated locus necessary for lipopolysaccharide modification, antimicrobial peptide resistance, and oral virulence of Salmonella enterica serovar typhimurium. Infect Immun. 2000; 68(11):6139-46. PMC: 97691. DOI: 10.1128/IAI.68.11.6139-6146.2000. View

Wang X, Ribeiro A, Guan Z, Abraham S, Raetz C . Attenuated virulence of a Francisella mutant lacking the lipid A 4'-phosphatase. Proc Natl Acad Sci U S A. 2007; 104(10):4136-41. PMC: 1820721. DOI: 10.1073/pnas.0611606104. View

Raetz C, Whitfield C . Lipopolysaccharide endotoxins. Annu Rev Biochem. 2002; 71:635-700. PMC: 2569852. DOI: 10.1146/annurev.biochem.71.110601.135414. View

Conlan J, Shen H, Webb A, Perry M . Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of.... Vaccine. 2002; 20(29-30):3465-71. DOI: 10.1016/s0264-410x(02)00345-6. View

Persing D, Coler R, Lacy M, Johnson D, Baldridge J, Hershberg R . Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol. 2002; 10(10 Suppl):S32-7. DOI: 10.1016/s0966-842x(02)02426-5. View

Vinogradov E, Perry M, Conlan J . Structural analysis of Francisella tularensis lipopolysaccharide. Eur J Biochem. 2002; 269(24):6112-8. DOI: 10.1046/j.1432-1033.2002.03321.x. View

Schwudke D, Linscheid M, Strauch E, Appel B, Zahringer U, Moll H . The obligate predatory Bdellovibrio bacteriovorus possesses a neutral lipid A containing alpha-D-Mannoses that replace phosphate residues: similarities and differences between the lipid As and the lipopolysaccharides of the wild type strain B..... J Biol Chem. 2003; 278(30):27502-12. DOI: 10.1074/jbc.M303012200. View

Coggins B, Li X, McClerren A, Hindsgaul O, Raetz C, Zhou P . Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nat Struct Biol. 2003; 10(8):645-51. PMC: 6783277. DOI: 10.1038/nsb948. View

Prior J, Prior R, Hitchen P, Diaper H, Griffin K, Morris H . Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J Med Microbiol. 2003; 52(Pt 10):845-851. DOI: 10.1099/jmm.0.05184-0. View

10.

Espevik T, Latz E, Lien E, Monks B, Golenbock D . Cell distributions and functions of Toll-like receptor 4 studied by fluorescent gene constructs. Scand J Infect Dis. 2003; 35(9):660-4. DOI: 10.1080/00365540310016493. View

11.

Miyake K . Endotoxin recognition molecules, Toll-like receptor 4-MD-2. Semin Immunol. 2004; 16(1):11-6. DOI: 10.1016/j.smim.2003.10.007. View

12.

Reis e Sousa C . Toll-like receptors and dendritic cells: for whom the bug tolls. Semin Immunol. 2004; 16(1):27-34. DOI: 10.1016/j.smim.2003.10.004. View

13.

Vinogradov E, Conlan W, Gunn J, Perry M . Characterization of the lipopolysaccharide O-antigen of Francisella novicida (U112). Carbohydr Res. 2004; 339(3):649-54. DOI: 10.1016/j.carres.2003.12.013. View

14.

Trent M . Biosynthesis, transport, and modification of lipid A. Biochem Cell Biol. 2004; 82(1):71-86. DOI: 10.1139/o03-070. View

15.

Miyake K . Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol. 2004; 12(4):186-92. DOI: 10.1016/j.tim.2004.02.009. View

16.

Conlan J . Vaccines against Francisella tularensis--past, present and future. Expert Rev Vaccines. 2004; 3(3):307-14. DOI: 10.1586/14760584.3.3.307. View

17.

Vinogradov E, Perry M . Characterisation of the core part of the lipopolysaccharide O-antigen of Francisella novicida (U112). Carbohydr Res. 2004; 339(9):1643-8. DOI: 10.1016/j.carres.2004.04.013. View

18.

Baldridge J, McGowan P, Evans J, Cluff C, Mossman S, Johnson D . Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther. 2004; 4(7):1129-38. DOI: 10.1517/14712598.4.7.1129. View

19.

Phillips N, Schilling B, McLendon M, Apicella M, Gibson B . Novel modification of lipid A of Francisella tularensis. Infect Immun. 2004; 72(9):5340-8. PMC: 517411. DOI: 10.1128/IAI.72.9.5340-5348.2004. View

20.

Holst O, Borowiak D, Weckesser J, Mayer H . Structural studies on the phosphate-free lipid A of Rhodomicrobium vannielii ATCC 17100. Eur J Biochem. 1983; 137(1-2):325-32. DOI: 10.1111/j.1432-1033.1983.tb07832.x. View